	Application Number		10803344
	Filing Date		2004-03-17
INFORMATION DISCLOSURE	First Named Inventor	Jerom	e C. Bressi
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1626
(Not to: Submission ander of of King)	Examiner Name	Debor	ah C. Lambkin
	Attorney Docket Numb	er	HDAC-5005-U

					U.S.F	PATENTS			Remove	(
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	of cited Document		s,Columns,Lines where ant Passages or Releval es Appear		
	1									
If you wish	n to ac	ld additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUBL	ICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines whe nt Passages or Rele s Appear	
	1									•
If you wisi	n to ac	ld additional U.S. Publis	shed Ap	plication	citation	n information p	lease click the Ad	button	Add	
				FOREIG	N PAT	ENT DOCUM	ENTS	•	Remove	
Examiner Initial*	Cite No	Foreign Document Number³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or _V F	Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	Т5
DL	1	WO 2005/034880	wo			2005-04-21	ATON PHARMA, I	NC.	·	
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button	Add	
			ОИ	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the au (book, magazine, joun publisher, city and/or of	nal, seri	al, symp	osium,	catalog, etc), o	the article (when a date, pages(s), vol	ppropria ume-iss	ate), title of the item ue number(s),	T5

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10803344
Filing Date	2004-03-17
First Named Inventor	Jerome C. Bressi
Art Unit	1626
Examiner Name	Deborah C. Lambkin
Attorney Docket Numb	er HDAC-5005-U

DL	1	Koruznjak et al., "Novel Derivatives of Benzo(b)thieno[2,3-c]quinolones: Synthesis, Photochemical Synthesis, and Antitumor Evaluation," J. Med. Chem., Vol. 46, No. 21, pp. 4516-4524 (2003).					
DL	DL 2 Wright et al., "The Preparation of 3-Chlorobenzo[b]thiophene Derivatives from Cinnamic Acids, J. Heterocyclic Chem., Vol. 8, No. 5, pp. 711-14 (1971).						
If you wis	h to ac	dd additional non-patent literature document citation information p	lease click the Add b	utton Add			
		EXAMINER SIGNATURE					
Examiner	Signa	iture Mondresse	Date Considered	9/20/80	•		
*EXAMIN citation if	ER: In	itial if reference considered, whether or not citation is in conforma conformance and not considered. Include copy of this form with i	nce with MPEP 609. next communication t	Draw line through a co applicant.			
Standard ST	r.3). ³ F cument	of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office For Japanese patent documents, the indication of the year of the reign of the Employ the appropriate symbols as indicated on the document under WIPO Standard anslation is attached.	eror must precede the seri	al number of the patent doc	ument		

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

nder the Barerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRADESTITUTE for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known				
Application Number	10/803,344			
Filing Date	March 17, 2004			
First Named Inventor	Jerome C. Bressi			
Group Art Unit	1626			
Examiner Name	Deborah C. Lambkin			
Attorney Docket Number	HDAC-5005-U			

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date/	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
initiais *	No.1	Number - Kind Code ² (if known)	Issue Date MM-DD-YYYY	0.000 0000	Passages or Relevant Figures Appear	
DL	AA	US 5,977,108	11/2/1999	Kouichi Kikuchi et al.		
DL	AB	US 6,099,851	8/8/2000	Kenneth M. Weisman et al.		
DL	AC	US 6,541,661	4/1/2003	Daniel Delorme et al.		

· · · ·		FOREIGN PA	TENT DOCU	MENTS	_	
		Foreign Patent Document		Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where	
Examiner Initials*	Date Date	Publication Date MM-DD-YYYY	Document Document	Relevant Passages or Relevant Figures Appear	Т ⁶	
DL	AD	EP 0 354 549 A2	2/14/1990	Konica Corporation		
DL	AE	EP 0 378 991 A1	7/25/1990	Ciba-Geigy AG		
DL	AF	JP 03 289654	12/19/1991	Konica Corporation		
DL	AG	EP 0 847 992 A1	6/17/1992	Mitsui Chemicals, Inc.		
DL	AH	EP 0570594 A	11/24/1993	SHIONOGI & CO., LTD.		
DL	Al	WO 97/29776 A1	8/21/1997	G.D. Searle & Co.		
	AJ	JP 11 095383	4/9/1999	Konica Corporation		
DL	AK	WO 01/70675	9/27/2001	METHYLGENE, INC.		
DL	AL	WO 02/26696	4/4/2002	PROLIFIX LIMITED		
DL	AM	WO 02/46129 A2	6/13/2002	Abbott Laboratories	<u> </u>	
DL	AN	WO 03/024448 A2 & A3	3/27/2003	Methylgene, Inc.	<u> </u>	
DL	AO	WO 03/039599 A1	5/15/2003	Novartis AG		L
DL	AP	WO 03/066579 A2	8/14/2003	Axys Pharmaceuticals	<u> </u>	
DL	AQ	WO 2004/046094	. 6/3/2004	Queen Mary & Westfield College		
DL	AR	WO 2005/019174	3/3/2005	Axys Pharmaceuticals, Inc.		
DL	AS	WO.2005/040161	5/6/2005	S*Bio PTE	<u> </u>	
DŢ	AT	WO 2005/040101	5/6/2005	S*Bio PTE		
DL	AU	WO 2005/073180	8/11/2005	JKUREHA CHEMICAL INDUSTRY COMPANY, LIMITED		<u> </u>
DL	AV	EP 0 847 992 A1	6/17/1992	Mitsui Chemicals, Inc.		

Examiner	/Deborah Lambkin/	Date	09/20/2006
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiallty is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	Substitute for form 1449A/PTO			Complete if Known
			Application Number	10/803,344
INFC	PRMATION I	DISCLOSURE	Filing Date	March 17, 2004
STA	TEMENT BY	/ APPLICANT	First Named Inventor	Jerome C. Bressi
			Group Art Unit	1626
	(use as many shee	ets as necessary)	Examiner Name	Deborah C. Lambkin
Sheet	2	of 2	Attorney Docket Number	HDAC-5005-U

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	•
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
DL	AW	Sasho, Setsuya et al. "Preparation and formulation of thiazole derivatives as cell adhesion inhibitors" Jpn. Kokai Tokkyo Koho, 42 pp. CA 127:17674 (1997)	
DL	AX	Wood, Warren J.L. et al. "Substrate activity screening: A fragment-based method for the rapid identification of nonpeptidic protease inhibitors." Journal of the American Chemical Society, (2005), 127(44), 15521-15527 143:452160	
DL	AY	Dai Yujia et al. "INdole amide hydroxamic acids as potent inhibitors of histone deacetylases." BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 11, 2 June 2003 (2003-06-02), pages 1897-1901, XP002331281 ISSN: 0960-894X abstract; figures 1,2; tables 1-4	
DL	AZ	DATABASE BEILSTEIN INSTITUT ZUR FORDERUNG DER WISSENCHAFTEN, FRANKFURT AM MAIN; DE; 2 December 1991 (12/2/1991), XP002331282 Database accession no. 4311238 abstract	
DL	ВА	DATABASE BEILSTEIN INSTITUT ZUR FORDERUNG DER WISSENCHAFTEN, FRANKFURT AM MAIN, DE; 2 December 1991 (12/2/1991), XP002331283 Database accession no. 5815061 abstract	
DL	ВВ	DATABASE BEILSTEIN INSTITUT ZUR FORDERUNG DER WISSENCHAFTEN, FRANKFURT AM MAIN, DE; 2 December 1991 (12/2/1991), XP002331284 Database accession no. 7765459 abstract	
DL	вс	DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2002 XP002325919 Database accession no. AN:2002:217200	
DL	BD	Lam, Patrick Y.S. et al. "Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticogulants" Journal of Medical Chemistry (2003), 46 (21) 4405-4418, CASREACT 140; 12453	

Examiner Signature	/Deborah Lambkin/	Date Considered	09/20/2006
-----------------------	-------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. ONOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.